UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No.__ )*

Artelo Biosciences Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

04301G102

(CUSIP Number)

September 19, 2018

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Continued on following pages

Page 1 of 9 Pages

_________________

* Alinga Capital LLC is the general partner and investment manager of Alinga Capital Fund LP (the “Fund”) in which such shares referred to above are held. As a result, Alinga Capital LLC possesses the power to vote and dispose or direct the disposition of all the shares owned by the Fund. The Fund owns 380,000 shares and further owns warrants to purchase an additional 230,000 shares (the “Fund Warrants”). Thus, Alinga Capital LLC may be deemed to beneficially own a total of 610,000 shares.

† Based on a total of (i) 14,002,293 shares outstanding of the Issuer as of September 26, 2018, as set forth in the Issuer’s most recent Form S-1, filed September 27, 2018, plus (ii) 230,000 shares issuable upon conversion of the Fund Warrants, as described in Rule 13d-3(d)(1)(i) under the Securities Exchange Act of 1934, as amended (“Exchange Act”).

_________________

† Based on a total of (i) 14,002,293 shares outstanding of the Issuer as of September 26, 2018, as set forth in the Issuer’s most recent Form S-1, filed September 27, 2018, plus (ii) 230,000 shares issuable upon conversion of the Fund Warrants, as described in Rule 13d-3(d)(1)(i) under the Exchange Act.

_________________

* Mr. Quilkey is the managing member of Alinga Capital LLC. As a result, Mr. Quilkey possesses the power to vote and dispose or direct the disposition of all the shares beneficially owned by Alinga Capital LLC as investment manager to the Fund. Mr. Quilkey disclaims beneficial ownership of any of the shares held by the Funds. In addition, Mr. Quilkey personally owns 337,500 shares and further owns warrants to purchase an additional 187,500 shares (the “Quilkey Warrants” and together with the Fund Warrants, the “Warrants”).

† Based on a total of (i) 14,002,293 shares outstanding of the Issuer as of September 26, 2018, as set forth in the Issuer’s most recent Form S-1, filed September 27, 2018, plus (ii) 417,500 shares issuable upon conversion of the Warrants, as described in Rule 13d-3(d)(1)(i) under the Exchange Act.

*Mr. Quilkey is the managing member of Alinga Capital LLC. As a result, Mr. Quilkey possesses the power to vote and dispose or direct the disposition of all the shares beneficially owned by Alinga Capital LLC as investment manager to the Fund. Mr. Quilkey disclaims beneficial ownership of any of the shares held by the Fund.

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

EXHIBIT A

Joint Filing Agreement

The Undersigned agree that the statements on Schedule 13G with respect to the common stock of Artelo Biosciences Inc. dated as of September 19, 2018, is, and any amendment thereto signed by each of the undersigned shall be, filed on behalf of each of them pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.